Stockreport

Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

Foghorn Therapeutics Inc.  (FHTX) 
PDF WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicin [Read more]